The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis
Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MedImmune; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst)
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst); Tolero Pharmaceuticals (Inst)
 
Harry Groen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst)
Research Funding - Roche (Inst)
 
Sayed MS Hashemi
Honoraria - AstraZeneca; Boehringer Ingelheim; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Takeda
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Tae Min Kim
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Bayer; Boryung; Novartis; Sanofi; Takeda; Voronoi Health Analytics
 
Elisabeth A. Quoix
Honoraria - Boehringer Ingelheim; Chugaï
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Roche (Inst); Transgene (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
 
Pierre Jean Souquet
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma Europe (Inst); merrimack (Inst); MSD Oncology; Novartis/Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Novartis; PFIZER; Roche/Genentech
Research Funding - Astellas Pharma (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Novartis; Novartis (Inst); Roche/Genentech (Inst); Sandoz (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; ROCHE; Takeda
 
Fabrice Barlesi
Other Relationship - Abbvie; ACEA Biosciences; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; F. Hoffmann LaRoche; Genentech; Innate Pharma; Ipsen; Lilly; Loxo; MedImmune; Merck; MSD; Novartis; Personal financial interests: Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda
 
Christina S Baik
No Relationships to Disclose
 
Liza C Villaruz
Consulting or Advisory Role - Achilles Therapeutics
Research Funding - AstraZeneca (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Rain Therapeutics (Inst)
 
Ronan Joseph Kelly
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Medscape; Merck; Novartis; Pieris Pharmaceuticals
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst)
 
Shirong Zhang
Employment - Novartis
 
Monique Tan
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Eduard Gasal
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Libero Santarpia
No Relationships to Disclose
 
Bruce E. Johnson
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; Foundation Medicine; Hengrui Therapeutics; Lilly; Novartis
Research Funding - Novartis (Inst); Novartis (Inst); Novartis (Inst); Toshiba (Inst)
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute